1. Eli Lilly Doubles Down on AI Drug Discovery with Multi-Billion Dollar Insilico Medicine Deal
Eli Lilly is aggressively expanding its AI-powered drug discovery pipeline, committing billions of dollars in a new strategic collaboration with Hong Kong-based biotech firm Insilico Medicine. This move signals a major escalation in the pharmaceutical industry's race to harness artificial intelligence for faster, more ...